E
Evergreen Theragnostics
Biotech & Life Sciences · Jersey City, United States · Founded 2019
Contract development and manufacturing of therapeutic radiopharmaceuticals MoreLess
Evergreen Theragnostics is a specialized company focused on the manufacturing, development, and distribution of therapeutic and diagnostic radiopharmaceuticals. The company operates in the biopharmaceutical sector, catering to clients involved in clinical trials and commercial radiopharmaceutical applications. Evergreen Theragnostics serves a diverse range of clients, including pharmaceutical companies, research institutions, and healthcare providers. The business model revolves around providing a broad range of services for centrally distributed radiopharmaceuticals, from early-phase clinical trials (Phase 0) through to full commercialization. Revenue is generated through service contracts, manufacturing agreements, and distribution deals. The company has established itself as a leader in the North American market, known for its unrivaled expertise and state-of-the-art production facilities. Evergreen Theragnostics recently completed a $19 million Series A capital raise, which will support the expansion of its manufacturing capabilities and further development of its service offerings.
Keywords: radiopharmaceuticals, manufacturing, development, distribution, clinical trials, commercialization, biopharmaceutical, healthcare, North America, expertise.
Company overview
Evergreen Theragnostics company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2019
- Headquarters
- Jersey City, United States
- Employees
- 60
- Open positions
- None listed
- Dealroom signal
- 60.6
Valuation & funding
Evergreen Theragnostics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jan 2025 | $250M | — | Lantheus Holdings | ↗ |
| GRANTOther financing | Apr 2024 | $26M | — | Petrichor · LIFTT | ↗ |
| SERIES BOther financing | Mar 2023 | $15M | $95M | Undisclosed | ↗ |
| SERIES AOther financing | Jun 2020 | $19M | $76M | Undisclosed | — |
Growth signals
Evergreen Theragnostics website traffic
Latest recorded traffic for Evergreen Theragnostics is 910 monthly website visits, down 52.1% over the last three months. Evergreen Theragnostics's team declined 38.1% over the past year.
Comparisons
Evergreen Theragnostics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Evergreen Theragnostics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Evergreen Theragnostics has talent and traffic
team presence
In the news
Latest news about Evergreen Theragnostics
Recent press, funding announcements, and product moves mentioning Evergreen Theragnostics — open to read from the original sources.
Market sentiment
What the market is saying about Evergreen Theragnostics
An AI-synthesized read of the highest-engagement posts about Evergreen Theragnostics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Evergreen Theragnostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.